Introduction {#sec1}
============

Liver and lung cancers are commonly diagnosed cancers with high mortality rate in China \[[@B1],[@B2]\]. Although great progress has been made in diagnosis and treatment of cancers over the past decade, the 5-year overall survival rates of lung and liver cancer patients remain low \[[@B3]\]. The major reason is that most patients are diagnosed at advanced stage, with consequently poor prognosis and limited treatment options. Therefore, it is emergent to identify certain inherited genetic variants associated with susceptibility to liver and lung cancer, which would be in favor of making early diagnosis and risk prediction.

Long non-coding RNAs (LncRNAs) are non-protein coding transcripts usually between 200 kb and 1000 kb in length and play important roles in diverse cellular processes, like growth, difference, apoptosis, epigenetic, and gene expression regulation \[[@B4]\]. Aberrant expression of lncRNAs has been identified in many cancer types, including liver and lung cancer, suggesting that lncRNAs might be involved in tumorigenesis and tumor progression \[[@B5]\]. In addition, single nucleotide polymorphism (SNP), which can affect the expression and function of genes, has been reported to be associated with susceptibility to many kinds of human complex diseases including cancer \[[@B6]\].

Rs3787016, which localizes to the fourth intron of RNA polymerase II polypeptide E (*POLR2E*) gene, has been studied by several researchers on its association with cancer risk \[[@B7]\]. However, the results remain conflicting rather than conclusive, probably due to the small sample size and different ethnic backgrounds of participants. To date, no study has been conducted to investigate the association between the risk of liver or lung cancer and *POLR2E* rs3787016 polymorphism. In view of this, a case--control study, based on 480 liver cancer patients, 550 lung cancer patients, and 800 normal controls, was conducted to evaluate the association between *POLR2E* rs3787016 and risk of lung and liver cancer in a Chinese population of Hubei province. Besides, we further carried out a meta-analysis, combining results from previous published literature and our case--control study, to clarify the real influence of rs3787016 on cancer risk.

Materials and methods {#sec2}
=====================

Participants {#sec2-1}
------------

The participants were consisted of 480 patients with histologically confirmed liver cancer, 550 patients with histologically confirmed lung cancer, and 800 cancer-free controls. The liver and lung cancer patients were volunteers recruited from Hubei Cancer Hospital and Wuhan Xinzhou District People's Hospital between January 2015 and December 2016, while the normal controls were selected from visitors who came to Wuhan Xinzhou District People's Hospital for regular physical examinations between September 2014 and December 2016. All subjects were biologically unrelated Han Chinese living in Hubei province. The present study was approved by the Ethical Committees of Wuhan University of Technology and written informed consent for the genetics analysis was obtained from all subjects or their guardians.

The genotyping of POLR2E rs3787016 polymorphism {#sec2-2}
-----------------------------------------------

Genomic DNA was extracted from venous blood using the TIANamp Blood DNA Kit (DP348, TianGen Biotech, Beijing) according to the manufacturer's instructions, and stored at −20°C before used. Polymerase chain reaction-restriction fragment length polymorphism (PCR--RFLP) was used to genotype the *POLR2E* rs3787016 polymorphism. The PCR primers were designed by Primer Premier 6.0 (PREMIER Biosoft), and the sequences were: 5′-CATCAACATCACGCAGCACG-3′(forward) and 5′-CCCTGTCCTCCAAGCACTCAT-3′(reverse). The PCR annealing temperature was 60°C. The transition of T \> C at rs3787016 polymorphism produces a *NLaIII* restriction site. Therefore, the 147 bp fragment of PCR product was then digested with *NLaIII* (Takara Biotechnology Co. Ltd, Dalian, China) overnight at 37°C, and the digested DNA fragmentations were evaluated by 2.5% agarose gel electrophoresis. The rs3787016 C allele results in two bands (127 bp and 20 bp), while the T allele produces one band (147 bp). For quality control, genotyping analysis was repeated twice. Furthermore, 20% randomly selected PCR-amplified DNA samples were examined by DNA sequencing, and the results were 100% concordant.

Statistical analysis {#sec2-3}
--------------------

All statistical analyses were performed by SPSS 15.0 software (SPSS, Chicago, IIIinois). The χ^2^ test was used to compare the differences in age, gender, smoking status, and drinking status between cancer patients and healthy controls. Hardy--Weinberg equilibrium (HWE) for rs3787016 genotype was tested by Pearson χ^2^ test statistics amongst the normal controls. Association between rs3787016 and cancer risk was assessed by unconditional logistic regression analysis with odds ratios (ORs) and 95% confidence intervals (CIs). Six genetic models, including T vs. C (allele model), TT vs. CT (carrier model: T carrier vs. C carrier), TT vs. CC (homozygote model), CT vs. CC (heterozygote model), TT vs. CT + CC (recessive model) and TT + CT vs. CC (dominant model) were used. The criterion of statistical significance was set at *P*\<0.05, and Bonferroni correction for multiple testing was applied \[[@B12]\].

Meta-analysis {#sec2-4}
-------------

We comprehensively searched the EMBASE, PubMed, ISI Web of Science, China National Knowledge Infrastructure, and WanFang databases updated to April 2018 to identify the eligible studies. The search details were shown in Supplementary Table S1. Flowchart of the search strategy and article selection for meta-analysis was demonstrated in [Figure 1](#F1){ref-type="fig"}. References listed in retrieved articles were also checked for missing information. Moreover, eligible studies were included while they met the following inclusion criteria: (1) studies on humans; (2) investigation of the POLR2E rs3787016 polymorphism and cancer risk; (3) case--control study design; (4) valid data were accessible to estimate the OR and its 95% CI; (5) HWE equilibrium should be established in control groups. Finally, five relevant articles were retrieved \[[@B7]\]. The Newcastle-Ottawa Scale (NOS) was used to assess the quality of included studies \[[@B13]\]. The meta-analysis was conducted by Review Manager 5.3 (Cochrane Collaboration). Different ethnicity descents were categorized as Asian and Caucasian. Heterogeneity was evaluated with the χ^2^ test and the inconsistency index (*I*^2^), and heterogeneity was considered significant when *P*\<0.1 was consistent with possible substantial heterogeneity. If *P*\<0.1, random-effects model was conducted to calculate the combined OR \[[@B14]\], otherwise, fixed-effect model we used \[[@B15]\]. The significance of combined ORs of the six genetic models (allele, carrier, homozygote, heterozygote, recessive, and dominant) was determined by the *Z* test. Further, sensitivity analysis was also tested by removing one study at a time, to evaluate the effect of removal and effect of size of each study on the homogeneity of the whole.

![Flow diagram of the literature review process for *POLR2E* rs3787016 polymorphism and cancer risk](bsr-38-bsr20180853-g1){#F1}

###### Characteristics of liver cancer patients, lung cancer patients, and normal controls

  Variables            Liver cancer patients (*n*=480)                  Lung cancer patients (*n*=550)   Normal controls (*n*=800)   *P* value[^2^](#T1TFN2){ref-type="table-fn"}   *P* value[^3^](#T1TFN3){ref-type="table-fn"}
  -------------------- ------------------------------------------------ -------------------------------- --------------------------- ---------------------------------------------- ----------------------------------------------
  **Age (years)**                                                                                                                                                                   
  ≤60                  280 (58.3%)[^1^](#T1TFN1){ref-type="table-fn"}   306 (55.6%)                      434 (54.3%)                 0.154                                          0.615
  \>60                 200 (41.7%)                                      244 (44.4%)                      366 (45.7%)                                                                
  **Gender**                                                                                                                                                                        
  Male                 343 (71.5%)                                      373 (67.9%)                      558 (69.7%)                 0.517                                          0.451
  Female               137 (28.5%)                                      177 (32.1%)                      242 (30.3%)                                                                
  **Smoking status**                                                                                                                                                                
  Ever                 140 (29.2%)                                      150 (27.3%)                      209 (26.1%)                 0.237                                          0.639
  Never                340 (70.8%)                                      400 (72.7%)                      591 (73.9%)                                                                
  **Alcohol status**                                                                                                                                                                
  Ever                 158 (32.9%)                                      170 (31.0%)                      237 (29.6%)                 0.217                                          0.613
  Never                322 (67.1%)                                      380 (69.0%)                      563 (70.4%)                                                                

Numbers in parentheses, percentage.

Age, gender, smoking status, and alcohol status distributions of liver cancer patients and normal controls were compared using two-sided χ^2^ test.

Age, gender, smoking status and alcohol status distributions of lung cancer patients and normal controls were compared using two-sided χ^2^ test.

Results {#sec3}
=======

Characteristics of participants {#sec3-1}
-------------------------------

[Table 1](#T1){ref-type="table"} showed us the main characteristics of participants. No significant differences for the distributions of age, gender, smoking status, and drinking status was identified between liver cancer patients and healthy controls, as well as between lung cancer patients and healthy controls. These results indicated that our case--control study was well matched based on these four variables.

Association of POLR2E rs3787016 polymorphism with risk of liver and lung cancer {#sec3-2}
-------------------------------------------------------------------------------

In the present study, rs3787016 was successfully genotyped in a total of 1830 participants. The allele and genotype distributions of rs3787016 and their association with risk of liver and lung cancer were presented in [Table 2](#T2){ref-type="table"}. The genotype frequencies of rs3787016 in normal controls showed no significant deviation from the HWE (*P*=0.205). As shown in [Table 2](#T2){ref-type="table"}, the allele and genotype distributions of rs3787016 showed no significant differences between liver or lung cancer patients and normal controls. Further logistic regression analysis under the six genetic models (T vs. C, TT vs. CT, TT vs. CC, CT vs. CC, TT vs. CT + CC, and TT + CT vs. CC) revealed no significant association between *POLR2E* rs3787016 and risk of liver or lung cancer.

###### Genotype and allele distributions of *POLR2E* rs3787016 polymorphism and its association with the risk of liver and lung cancer

  POLR2E rs3787016   I. Liver cancer patients (*n*=480)             II\. Lung cancer patients (*n*=550)   III\. Normal controls (*n*=800)   *P* value[^2^](#T2TFN2){ref-type="table-fn"}   Logistic regression \[*P*, OR (95% CI)\][^3^](#T2TFN3){ref-type="table-fn"}                                                  
  ------------------ ---------------------------------------------- ------------------------------------- --------------------------------- ---------------------------------------------- ----------------------------------------------------------------------------- ------------------ --------------------------- ---------------------------
  T                  576 (60%)[^1^](#T2TFN1){ref-type="table-fn"}   612 (55.6%)                           936 (58.5%)                       0.455                                          0.139                                                                         T vs. C            0.455, 1.06 (0.90--1.25)    0.139, 0.890 (0.76--1.04)
  C                  384 (40%)                                      488 (44.4%)                           664 (41.5%)                                                                                                                                                                                                   
  TT                 188 (39.2%)                                    181 (32.9%)                           286 (35.8%)                       0.373                                          0.346                                                                         TT vs*.* CT        0.164, 1.20 (0.93--1.54)    0.515, 0.92 (0.72--1.18)
  CT                 200 (41.7%)                                    250 (45.5%)                           364 (45.5%)                                                                                                                                                    TT vs*.* CC        0.669, 1.07 (0.78--1.47)    0.145, 0.80 (0.59--1.08)
  CC                 92 (19.2%)                                     119 (21.6%)                           150 (18.8%)                                                                                                                                                    CT vs*.* CC        0.489, 0. 96 (0.66--1.22)   0.329, 0.87 (0.65--1.16)
                                                                                                                                                                                                                                                                         TT vs*.* CT + CC   0.221, 1.16 (0.92--1.46)    0.281, 0.88 (0.70--1.11)
                                                                                                                                                                                                                                                                         TT + CT vs*.* CC   0.854, 0.97 (0.73--1.29)    0.192, 0.84 (0.64--1.10)

Numbers in parentheses, percentage.

The frequencies of allele and genotype in cancer patients and normal controls were compared using two-sided χ^2^ test.

The *P* value was calculated using two-sided χ^2^ test. OR (95% CI) was estimated by logistic regression analysis.

Stratified analysis of the association between rs3787016 polymorphism with risk of liver and lung cancer according to age, gender, smoking status, and alcohol status {#sec3-3}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------

Considering the importance of age, gender, smoking, and drinking in liver and lung carcinogenesis \[[@B16],[@B17]\]; thus, we conducted a stratified analysis of rs3787016 according to these four variables. All genotype frequencies of rs3787016 were consistent with the HWE amongst normal controls in each subgroup (*P*\>0.05). According to the results in [Table 3](#T3){ref-type="table"}, it was interestingly to find an increased liver cancer risk for rs3787016 T allele and TT genotype in older participants (T vs*.* C: *P*=0.005, OR = 1.44, 95% CI = 1.12--1.86; TT vs*.* CC: *P*=0.005, OR = 2.22, 95% CI = 1.27--3.89) and ever drinking participants (T vs*.* C: *P*=0.002, OR = 1.58, 95% CI = 1.18-2.12; TT vs*.* CC: *P*=0.003, OR = 2.49, 95% CI = 1.36--4.58) even after Bonferroni correction (*P*\<0.008, 0.05/6). These results suggested potential interactions amongst rs3787016, aging, and drinking in the etiology of liver cancer. However, our results revealed no significant association between rs3787016 and lung cancer risk in none of the stratified analysis by age, gender, smoking status, and drinking status.

###### Stratification analyses of *POLR2E* rs3787016 genotype and allele according to age, gender, smoking status, and drinking status

  Groups                  Allele   Genotype   Logistic regression \[*P*, OR (95% CI)\][^2^](#T3TFN2){ref-type="table-fn"}                                                                                                                                                              
  ----------------------- -------- ---------- ----------------------------------------------------------------------------- ----- ----- ------- -------------------------- -------------------------- -------------------------- -------------------------- -------------------------- --------------------------
  **≤60 years**                                                                                                                                                                                                                                                                        
  Liver cancer patients   310      250        101                                                                           108   71            0.176, 0.86 (0.70--1.07)   0.573, 1.10 (0.78--1.56)   0.131, 0.73 (0.49--1.10)   0.043, 0.66 (0.45--0.99)   0.781, 0.96 (0.70--1.31)   0.049, 0.70 (0.49--1.00)
  Lung cancer patients    341      271        101                                                                           139   66            0.210, 0.88 (0.71--1.08)   0.363, 0.86 (0.62--1.19)   0.255, 0.79 (0.53--1.19)   0.675, 0.92 (0.62--1.36)   0.252, 0.84 (0.61--1.14)   0.414, 0.86 (0.60--1.24)
  Normal controls         512      356        161                                                                           190   83    0.139                                                                                                                                          
  **\>60 years**                                                                                                                                                                                                                                                                       
  Liver cancer patients   266      134        87                                                                            92    21            0.005, 1.44 (1.12--1.86)   0.148, 1.32 (0.91--1.91)   0.005, 2.22 (1.27--3.89)   0.063,1.69 (0.97--2.93)    0.028, 1.48 (1.04--2.11)   0.016, 1.91 (1.13--3.23)
  Lung cancer patients    271      217        80                                                                            111   53            0.409, 0.91 (0.72--1.14)   0.986, 1.00 (0.69--1.45)   0.363, 0.81 (0.51--1.27)   0.329, 0.81 (0.52--1.24)   0.726, 0.94 (0.67--1.33)   0.299, 0.81 (0.54--1.21)
  Normal controls         424      308        125                                                                           174   67    0.895                                                                                                                                          
  **Male**                                                                                                                                                                                                                                                                             
  Liver cancer patients   411      275        134                                                                           143   66            0.583, 1.06 (0.87--1.28)   0.255, 1.19 (0.88--1.61)   0.779, 1.06 (0.72--1.54)   0.526, 0.89 (0.61--1.29)   0.331, 1.15 (0.87--1.52)   0.822, 0.96 (0.68--1.35)
  Lung cancer patients    416      330        123                                                                           170   80            0.225, 0.89 (0.74--1.07)   0.577, 0.92 (0.68--1.24)   0.233, 0.80 (0.55--1.16)   0.436, 0.87 (0.61--1.24)   0.368, 0.88 (0.67--1.16)   0.292, 0.84 (0.61--1.16)
  Normal controls         654      462        200                                                                           254   104   0.344                                                                                                                                          
  **Female**                                                                                                                                                                                                                                                                           
  Liver cancer patients   165      109        54                                                                            57    26            0.599, 1.08 (0.80--1.47)   0.420, 1.21 (0.76--1.93)   0.726, 1.11 (0.62--2.00)   0.768, 0.92 (0.52--1.63)   0.452, 1.18 (0.77--1.82)   0.994, 1.00 (0.59--1.71)
  Lung cancer patients    196      158        58                                                                            80    39            0.403, 0.89 (0.67--1.17)   0.737, 0.93 (0.60--1.44)   0.407, 0.80 (0.46--1.37)   0.559, 0.86 (0.51--1.44)   0.556, 0.88 (0.59--1.33)   0.447, 0.83 (0.51--1.34)
  Normal controls         282      202        86                                                                            110   46    0.596                                                                                                                                          
  **Ever-smoking**                                                                                                                                                                                                                                                                     
  Liver cancer patients   168      112        55                                                                            58    27            0.715, 1.06 (0.78--1.44)   0.452, 1.20 (0.75--1.94)   0.851, 1.06 (0.58--1.93)   0.676, 0.88 (0.49--1.59)   0.520, 1.16 (0.74--1.80)   0.884, 0.96 (0.56--1.66)
  Lung cancer patients    168      132        50                                                                            68    32            0.485, 0.90 (0.67--1.21)   0.769, 0.93 (0.58--1.50)   0.489, 0.81 (0.45--1.46)   0.634, 0.87 (0.50--1.53)   0.617, 0.89 (0.57--1.39)   0.531, 0.85 (0.50--1.43)
  Normal controls         245      173        75                                                                            95    39    0.660                                                                                                                                          
  **Never-smoking**                                                                                                                                                                                                                                                                    
  Liver cancer patients   408      272        133                                                                           142   65            0.515, 1.07 (0.88--1.29)   0.242, 1.19 (0.89--1.61)   0.701, 1.07 (0.74--1.57)   0.580, 0.90 (0.62--1.30)   0.299, 1.16 (0.88--1.52)   0.900, 0.98 (0.70--1.36)
  Lung cancer patients    444      356        131                                                                           182   87            0.191, 0.89 (0.74--1.06)   0.559, 0.92 (0.69--1.22)   0.199, 0.79 (0.56--1.13)   0.394,0.86 (0.62--1.21)    0.338, 0.88 (0.67--1.15)   0.252, 0.83 (0.61--1.14)
  Normal controls         691      491        211                                                                           269   111   0.311                                                                                                                                          
  **Ever-drinking**                                                                                                                                                                                                                                                                    
  Liver cancer patients   206      110        68                                                                            70    20            0.002, 1.58 (1.18--2.12)   0.151, 1.39 (0.89--2.16)   0.003, 2.49 (1.36--4.58)   0.053, 1.80 (0.99--3.26)   0.021, 1.63 (1.08--2.48)   0.010, 2.09 (1.19--3.64)
  Lung cancer patients    181      159        51                                                                            79    40            0.781, 0.96 (0.73--1.27)   0.726, 0.92 (0.58--1.46)   0.808, 0.94 (0.54--1.61)   0.953, 1.02 (0.62--1.67)   0.723, 0.93 (0.60--1.42)   0.940, 0.98 (0.62--1.56)
  Normal controls         257      217        75                                                                            107   55    0.378                                                                                                                                          
  **Never-drinking**                                                                                                                                                                                                                                                                   
  Liver cancer patients   370      274        120                                                                           130   72            0.241, 0.89 (0.73--1.08)   0.456, 1.12 (0.83--1.53)   0.138, 0.75 (0.51--1.10)   0.033, 0.67 (0.46--0.97)   0.950, 0.99 (0.75--1.32)   0.045, 0.71 (0.50--0.99)
  Lung cancer patients    431      329        130                                                                           171   79            0.120, 0.86 (0.72--1.04)   0.605, 0.93 (0.69--1.24)   0.112, 0.74 (0.51--1.07)   0.219, 0.80 (0.56--1.14)   0.306, 0.87 (0.66--1.14)   0.129, 0.77 (0.56--1.08)
  Normal controls         679      447        211                                                                           257   95    0.543                                                                                                                                          

Genotypic frequency of rs3787016 in normal controls was tested for departure from HWE using the χ^2^ test.

For each stratified factor, the *P* value and OR (95% CI) were calculated using two-sided χ^2^ test and logistic regression analysis. First row for 'Liver cancer patients vs*.* Normal controls', second row for 'Lung cancer patients vs*.* Normal controls'.

Results of meta-analysis {#sec3-4}
------------------------

As shown in Supplementary Table S2, the NOS score of all articles are not \<6, indicating that each included literature was a high-quality study. The main features of the five previous studies and current study were demonstrated in [Table 4](#T4){ref-type="table"}. All studies were consistent with HWE in normal controls (*P*\>0.05). Similarly, the adjusted *P* value (\<0.008, 0.05/6) using Bonferroni correction was applied. In [Table 5](#T5){ref-type="table"}, we observed that *POLR2E* rs3787016 was associated with cancer risk under the TT vs*.* CT model (*P*\<1 × 10^−3^, OR = 1.20, 95% CI = 1.09--1.33) and TT vs. CT+TT model (*P*=0.006, OR = 1.22, 95% CI = 1.06--1.41), suggesting that the carriers with rs3787016 TT genotype had a significantly increased cancer risk compared with the CT/CC genotypes carriers ([Figure 2](#F2){ref-type="fig"}). Further, we performed a sensitivity analysis to examine the stability of the pooled ORs with the effect of the individual studies. With removal of individual study results from the analysis for rs3787016, the pooled ORs remained significantly consistent ([Figure 3](#F3){ref-type="fig"}). Next, stratified analysis according to ethnicity and cancer type was conducted. Interestingly, we found that rs3787016 was significantly associated with cancer risk in Caucasian population but not in Asian (Chinese) population. Moreover, the T allele and T variant genotypes of rs3787016 were associated with a significantly higher prostate cancer risk under the six genetic models (T vs. C, TT vs. CT, TT vs. CC, CT vs. CC, TT vs. CT+CC, and TT +CT vs. CC).

###### Characteristics of the current and previous studies

  References (author, year)   Ethnicity (Country)   Cancer type         Genotyping assay   Case, control (*n*)   HWE[^1^](#T4TFN1){ref-type="table-fn"}                                  
  --------------------------- --------------------- ------------------- ------------------ --------------------- ---------------------------------------- ------------------------------ -------
  Cao et al. \[[@B9]\]        Asian (China)         Prostate cancer     PCR--RFLP          1015, 1032            891/1139, 826/1238                       189/513/313, 151/524/357       0.180
  Kang et al. \[[@B10]\]      Asian (China)         Esophageal cancer   PCR--RFLP          369, 370              329/409, 336/404                         90/149/130, 71/194/105         0.268
  Xu et al. \[[@B11]\]        Asian (China)         Breast Cancer       MassARRAY          439, 439              395/483, 354/524                         93/209/137, 64/226/149         0.344
  The present study           Asian (China)         Liver cancer        PCR--RFLP          480, 800              576/384, 936/664                         188/200/92, 286/364/150        0.205
  The present study           Asian (China)         Lung cancer         PCR--RFLP          550, 800              612/488, 936/664                         181/250/119, 286/364/150       0.205
  Jin et al. \[[@B7]\]        Caucasian (U.S.A.)    Prostate cancer     TaqMan assay       4196, 5007            2232/6160, 2354/7660                     297/1638/2261, 277/1800/2930   0.997
  Nikolic et al. \[[@B8]\]    Caucasian (Serbia)    Prostate cancer     TaqMan assay       261, 106              142/380, 58/154                          21/100/140, 7/44/55            0.648

Genotypic frequency of rs3787016 in normal controls was tested for departure from HWE using the χ^2^ test.

###### Meta-analysis of *POLR2E* rs3787016 polymorphism and cancer risk

  Genetic model                                      Heterogeneity test   Summary OR (95% CI)   Hypothesis test   Number                                                    
  -------------------------------------------------- -------------------- --------------------- ----------------- ------------------- ------ -------------- ------- ------- ---
  **rs3787016 and cancer risk**                                                                                                                                             
  T vs*.* C                                          14.7                 0.023                 59%               1.08 (0.99--1.18)   1.70   0.089          14620   17108   7
  TT vs*.* CT                                        9.54                 0.145                 37%               1.20 (1.09--1.33)   3.59   \<1 × 10^−3^   4118    4658    7
  TT vs. CC                                          14.0                 0.030                 57%               1.20 (0.99--1.44)   1.86   0.063          4251    5038    7
  CT vs. CC                                          19.1                 0.004                 69%               0.96 (0.81--1.13)   0.51   0.608          6251    7412    7
  TT vs. CT+CC                                       11.4                 0.076                 48%               1.22 (1.06--1.41)   2.76   0.006          7310    8554    7
  TT+CT vs. CC                                       16.9                 0.011                 65%               1.02 (0.88--1.18)   0.28   0.782          7310    8554    7
  **rs3787016 and cancer risk in Asian (Chinese)**                                                                                                                          
  T vs*.* C                                          10.1                 0.039                 60%               1.06 (0.94--1.19)   0.93   0.352          5706    6882    5
  TT vs*.* CT                                        9.42                 0.051                 58%               1.26 (1.03--1.53)   2.25   0.024          2062    2530    5
  TT vs. CC                                          11.2                 0.025                 64%               1.14 (0.89--1.46)   1.06   0.290          1532    1769    5
  CT vs. CC                                          9.32                 0.049                 58%               0.90 (0.75--1.10)   1.02   0.308          2112    2583    5
  TT vs. CT+CC                                       10.5                 0.032                 62%               1.21 (1.00--1.48)   1.91   0.056          2853    3441    5
  TT+CT vs. CC                                       9.73                 0.045                 59%               0.97 (0.81--1.17)   0.30   0.764          2853    3441    5
  **rs3787016 and cancer risk in Caucasian**                                                                                                                                
  T vs. C                                            0.86                 0.353                 0%                1.17 (1.10--1.25)   4.73   \<1 × 10^−3^   8914    10226   2
  TT vs. CT                                          0.06                 0.813                 0%                1.18 (1.00--1.41)   1.90   0.058          2056    2128    2
  TT vs. CC                                          0.12                 0.728                 0%                1.38 (1.17--1.64)   3.73   \<1 × 10^−3^   2719    3269    2
  CT vs. CC                                          1.29                 0.256                 23%               1.17 (1.07--1.27)   3.59   \<1 × 10^−3^   4139    4829    2
  TT vs. CT+CC                                       0.01                 0.914                 0%                1.30 (1.10--1.53)   3.08   0.002          4457    5113    2
  TT+CT vs. CC                                       1.22                 0.270                 18%               1.20 (1.10--1.30)   4.33   \<1 × 10^−3^   4457    5113    2
  **rs3787016 and prostate cancer risk**                                                                                                                                    
  T vs. C                                            0.86                 0.650                 0%                1.17 (1.11--1.24)   5.36   \<1 × 10^−3^   10944   12290   3
  TT vs. CT                                          0.31                 0.856                 0%                1.21 (1.05--1.40)   2.68   0.007          2758    2803    3
  TT vs. CC                                          0.16                 0.921                 0%                1.39 (1.21--1.61)   4.58   \<1 × 10^−3^   3221    3777    3
  CT vs. CC                                          1.47                 0.480                 0%                1.16 (1.07--1.25)   3.73   \<1 × 10^−3^   4965    5710    3
  TT vs. CT+CC                                       0.05                 0.976                 0%                1.31 (1.14--1.50)   3.91   \<1 × 10^−3^   5472    6145    3
  TT+CT vs*.* CC                                     1.23                 0.542                 0%                1.20 (1.11--1.29)   4.70   \<1 × 10^−3^   5472    6145    3
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Discussion {#sec4}
==========

LncRNAs play important roles in diverse human diseases including cancer, and abnormal expression of lncRNAs is a common feature of many human cancers \[[@B4],[@B5]\]. Since SNPs can affect the gene expression and function \[[@B18]\], the lncRNAs polymorphisms have been widely studied to explore their associated with cancer risk \[[@B6]\].

The rs3787016 polymorphism, locates in an intron of *POLR2E* gene, was first reported in a genome-wide association study of prostate cancer \[[@B7]\]. Jin et al. \[[@B7]\] identified that *POLR2E* rs3787016 polymorphism was associated with prostate cancer susceptibility in Caucasian population. Subsequently, two replication studies on the possible association between rs3787016 and prostate cancer risk were conducted \[[@B8],[@B9]\]. However, the significant association was found in Chinese population \[[@B9]\] but not in Serbian population \[[@B8]\]. Since a small number of subjects from Serbian population were included and different ethnic groups, we reasoned that the inconsistent results might be attributed to the differences in sample size and ancestral backgrounds.

Interestingly, Kang et al. \[[@B10]\] and Xu et al. \[[@B11]\] also revealed a significant association between rs3787016 with risk of esophageal cancer and breast cancer, which highlighted that *POLR2E* rs3787016 polymorphism might servers as a common genetic factor to affect individual susceptibility to cancer. To address this issue, for the first time, we here evaluated the association between rs3787016 and risk of liver and lung cancer. Although no significant association was found for rs3787016 and liver cancer or lung cancer risk, the further stratified analysis of rs3787016 according to age, gender, smoking status, and drinking status identified that rs3787016 exerted its effect on liver cancer risk particularly for over than 60 years individuals who drink. The interpretation of such finding might be as follow: aging and drinking might induce a variety of DNA damage or risk mutations and thus initiate liver carcinogenesis \[[@B19],[@B20]\], and the effect of rs3787016 on liver cancer risk might be augmented by the factors of age and drinking. However, the interactions amongst rs3787016, aging and drinking in the etiology of liver cancer still needs to be investigated in further study.

Actually, Chu et al. \[[@B21]\] have performed a meta-analysis to evaluate the association between rs3787016 and cancer risk, which included the same studies \[[@B7]\]. However, we found that the data in study of Nikolic et al. \[[@B8]\] was wrongly extracted by Chu et al. Moreover, given the newly generated experiment data in current case--control study, we futher perform a rigorous and updated meta-analysis to determine the association of *POLR2E* rs3787016 polymorphism and cancer risk. We observed that rs3787016 was significantly associated with cancer risk in total population, and rs3787016 TT genotype contributed to a higher risk of cancer risk. However, the significant association remained in Caucasian population but not in Asian (Chinese) population, indicating that differences in genetic background may be a possible reflection of rs3787016 on cancer risk. In addition, the stratified analysis according to cancer type showed that the rs3787016 was associated with prostate cancer risk. However, further studies with larger sample size in different ethnic populations and in prostate cancer are warranted.

Admittedly, several limitations of the present study should be acknowledged. First, since a hospital-based case--control study was used, the potential for selection bias should be considered. Second, the underlying molecular mechanism for the contribution of rs937283 to cancer susceptibility remained unknown, which will be explored in future functional studies. Third, our current findings of this case--control study only involved Han Chinese population, thus further confirmatory studies in different ethnic groups are needed. Fourth, since the publication bias can be evaluated for meta-analysis with sufficient numbers of included studies (*n*\>10), the assessment of publication bias was not performed through Begg's funnel plot and Egger's linear regression method \[[@B22]\]. Therefore, we could not eliminate the possibility of publication bias in the present study meta-analysis. Fifth, a high degree of heterogeneity was observed in the meta-analysis of rs3787016 and overall cancer risk in total population and Asian (Chinese) population. The variations of different cancer types, clinical characteristics, ethnicity, geographical location and so on were not fully considered. Sixth, due to the relatively small number of included studies, the subgroup analysis by cancer type only performed for prostate cancer, while for others, such as breast cancer and liver cancer, which should be investigated in the future. Finally, the *POLR2E* rs3787016 polymorphism may not be the causal loci, but may just be in linkage disequilibrium with the causal loci.

In summary, our results demonstrated that *POLR2E* rs3787016 polymorphism may be associated with the risk of liver cancer for over than 60 years Chinese individuals who drink. Moreover, the following meta-analysis revealed that *POLR2E* rs3787016 polymorphism may be associated with overall cancer risk and prostate cancer risk. Before these reported findings will contribute to clinical decision-making, additional studies with a larger sample size and in different ethnic populations are needed to confirm or further reinforce our present findings.
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